4552 JCR Pharmaceuticals Co.,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4552

TSE Prime

JCR Pharmaceuticals Co.,Ltd.

718

JPY

+12

(+1.70%)

Dec 5, 3:09 pm JST

4.64

USD

Dec 5, 1:09 am EST

Result

PTS

outside of trading hours

717.9

Dec 5, 3:09 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	51,082	19,933	20,512	14,507	117.3	22	May 12, 2022	J-GAAP
Mar, 2023	34,343	4,975	5,418	3,772	30.4	20	May 11, 2023	J-GAAP
Mar, 2024	42,871	7,531	7,264	5,507	44.1	20	May 10, 2024	J-GAAP
Mar, 2025	33,072	-6,650	-7,477	-4,759	-38.4	20	May 13, 2025	J-GAAP
Mar, 2026 Guidance	37,800	2,600	2,400	3,000	24.6	20	May 13, 2025	J-GAAP
YoY	+14.3%	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 12, 2020	27,200	6,000	6,000	4,800	9*	J-GAAP
	Mar 25, 2021	30,000	9,000	9,100	7,100	9*	J-GAAP
Results	May 13, 2021	30,085	8,269	8,488	6,892	12*	J-GAAP
Mar, 2022	May 13, 2021	Available in future release
	Sep 30, 2021
	Oct 28, 2021
Results	May 12, 2022
Mar, 2023	May 12, 2022
	Mar 30, 2023
Results	May 11, 2023
Mar, 2024	May 11, 2023
	Sep 28, 2023
Results	May 10, 2024
Mar, 2025	May 10, 2024
	Jan 31, 2025
	Mar 27, 2025
Results	May 13, 2025
Mar, 2026	May 13, 2025	37,800	2,600	2,400	3,000	20	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	8,576	+18.2	Available in future release
Mar, 2002	8,114	-5.4
Mar, 2003	7,581	-6.6
Mar, 2004	7,476	-1.4
Mar, 2005	8,099	+8.3
Mar, 2006	7,648	-5.6
Mar, 2007	8,544	+11.7
Mar, 2008	11,871	+38.9
Mar, 2009	12,082	+1.8
Mar, 2010	14,387	+19.1
Mar, 2011	14,457	+0.5
Mar, 2012	12,845	-11.2
Mar, 2013	14,099	+9.8
Mar, 2014	15,705	+11.4
Mar, 2015	16,855	+7.3
Mar, 2016	17,438	+3.5
Mar, 2017	18,085	+3.7
Mar, 2018	20,594	+13.9
Mar, 2019	23,160	+12.5
Mar, 2020	24,781	+7.0
Mar, 2021	30,085	+21.4
Mar, 2022	51,082	+69.8
Mar, 2023	34,343	-32.8
Mar, 2024	42,871	+24.8
Mar, 2025	33,072	-22.9
Mar, 2026 Guidance	37,800	+14.3	2,600	－	2,400	－	24.6	－

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	42,871	7,531	17.6	10.31	5.59	0.43	44.1
Mar, 2025	33,072	-6,650	-20	-9.30	-4.60	0.32	-38.4
Mar, 2026 Guidance	37,800	2,600	6.88	6.24	2.75	0.35	24.6

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	51,082	19,933	20,512	14,507	117.3
Fiscal Year	Mar, 2022	Mar, 2022	Mar, 2022	Mar, 2022	Mar, 2022

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	18,762	4,231	3,849	2,810	22.6	10	May 11, 2023	J-GAAP
Oct - Mar, 2023	18,599	633	138	254	2.0	10	May 10, 2024	J-GAAP
Oct - Mar, 2024	16,415	-5,911	-5,856	-4,068	-32.9	10	May 13, 2025	J-GAAP
Oct - Mar, 2025 Guidance	16,438	221	38	1,290	10.6	10	Oct 30, 2025	J-GAAP
YoY	+0.1%	－	－	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	4,975	-20,502	-5,500	-15,002	1,948	13,278	13.99	J-GAAP
Mar, 2024	7,531	6,622	9,312	-2,690	-2,031	18,756	18.35	J-GAAP
Mar, 2025	-6,650	-15,360	-5,486	-9,874	9,736	13,196	12.58	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2023	24,272	6,898	7,126	5,253	42.1	98.1	Oct 25, 2023	J-GAAP
Apr - Sep, 2024	16,657	-739	-1,621	-691	-5.5	ー	Oct 30, 2024	J-GAAP
Apr - Sep, 2025	21,362	2,379	2,362	1,710	14.0	98.4	Oct 30, 2025	J-GAAP
YoY	+28.2%	－	－	－	－

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	9,446	911	262	-93	-0.8	9.6	Jan 26, 2024	J-GAAP
Jan - Mar, 2024	9,153	-278	-124	347	2.8	-3.0	May 10, 2024	J-GAAP
Apr - Jun, 2024	8,145	-296	-257	201	1.6	-3.6	Jul 30, 2024	J-GAAP
Jul - Sep, 2024	8,512	-443	-1,364	-892	-7.1	-5.2	Oct 30, 2024	J-GAAP
Oct - Dec, 2024	9,223	-15	241	115	0.9	-0.2	Jan 31, 2025	J-GAAP
Jan - Mar, 2025	7,192	-5,896	-6,097	-4,183	-33.8	-82.0	May 13, 2025	J-GAAP
Apr - Jun, 2025	8,569	-606	-749	-546	-4.5	-7.1	Jul 30, 2025	J-GAAP
Jul - Sep, 2025	12,793	2,985	3,111	2,256	18.5	23.3	Oct 30, 2025	J-GAAP
YoY	+50.3%	－	－	－	－

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	8,473	+23.9	Available in future release
Jan - Mar, 2021	10,661	+59.0
Apr - Jun, 2021	9,813	+89.4
Jul - Sep, 2021	18,570	+221.8
Oct - Dec, 2021	11,887	+40.3
Jan - Mar, 2022	10,812	+1.4
Apr - Jun, 2022	9,606	-2.1
Jul - Sep, 2022	5,975	-67.8
Oct - Dec, 2022	11,115	-6.5
Jan - Mar, 2023	7,647	-29.3
Apr - Jun, 2023	10,808	+12.5
Jul - Sep, 2023	13,464	+125.3
Oct - Dec, 2023	9,446	-15.0
Jan - Mar, 2024	9,153	+19.7
Apr - Jun, 2024	8,145	-24.6
Jul - Sep, 2024	8,512	-36.8
Oct - Dec, 2024	9,223	-2.4
Jan - Mar, 2025	7,192	-21.4
Apr - Jun, 2025	8,569	+5.2
Jul - Sep, 2025	12,793	+50.3	2,985	－	3,111	－	18.5	－

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	18,570	10,656	10,731	7,702	62.3
Fiscal Year	Sep, 2021	Sep, 2021	Sep, 2021	Sep, 2021	Sep, 2021

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	412.11	54.2	94,937	51,421	34,273	0.44	May 11, 2023	J-GAAP
Mar, 2024	443.62	54.2	102,226	55,365	37,278	0.42	May 10, 2024	J-GAAP
Mar, 2025	385.50	44.8	104,855	46,967	31,191	0.81	May 13, 2025	J-GAAP
Apr - Sep, 2025	ー	44.1	109,055	48,080	31,681	0.83	Oct 30, 2025	J-GAAP

JCR Pharmaceuticals Co.,Ltd.(4552) Financial Results